Research programme: antbody-drug conjugates - LegoChem/Nordic Nanovector

Drug Profile

Research programme: antbody-drug conjugates - LegoChem/Nordic Nanovector

Alternative Names: anti-CD37 ADC - Nordic Nanovector; anti-CD37 antibody - Nordic Nanovector; LCB14 15XX - LegoChem/Nordic Nanovector

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LegoChem Biosciences; Nordic Nanovector
  • Developer Nordic Nanovector
  • Class Antibodies; Antineoplastics; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Leukaemia

Most Recent Events

  • 10 Oct 2016 Nordic NanoVector and LegoChem Biosciences enter a research collaboration for antibody-drug conjugates
  • 10 Oct 2016 Early research in Leukaemia in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top